H.C. Wainwright raised the firm’s price target on Eton Pharmaceuticals (ETON) to $35 from $33 and keeps a Buy rating on the shares after the company announced that Khindivi received FDA approval as replacement therapy in pediatric patients five years of age and older with adrenal insufficiency. The firm believes 2025 could be a year of revenue inflection for Eton.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETON:
- Eton Pharmaceuticals: Buy Rating Affirmed on Khindivi’s FDA Approval and Strong Revenue Growth Prospects
- Eton Pharmaceuticals Gains FDA Approval for KHINDIVI
- Eton Pharmaceuticals announces FDA approval for KHINDIVI
- Eton Pharmaceuticals price target raised to $26 from $24 at B. Riley
- Eton Pharmaceuticals’ Earnings Call: Growth and Prospects